Skip to main content
Clinical Trials/NCT06908967
NCT06908967CompletedNot Applicable

An Open-label, Single-blinded, Randomized, 2-way Crossover, Performance Study of the EyeMirage (Test Device) Relative to Standard of Care (Reference Device) in Patients Undergoing Standard Eye Examinations for Various Conditions

Neuroptek Corporation Inc.4 sites in 1 country160 target enrollmentStarted: June 13, 2025Last updated:
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
160
Locations
4
Primary Endpoint
Accuracy and Reliability of EyeMirage Test Results from Four Elements of Visual Testing in Comparison to Current Standard of Care

Study Overview

Brief Summary

This study will assess the effectiveness and accuracy of results of a new device for eye function testing. This will be done by comparing results of four eye tests that are done through the current standard used in eye clinics and that of this new device. Participants of this study will undergo the four eye tests using both the new device and the standard of care devices.

The study will be done in one visit to the eye clinic. Thirty days after the eye tests were done, participants will be called by the clinic for a general follow-up and to discuss any problems, if needed.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Screening
Masking
Single (Investigator)

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Evidence of a signed and dated informed consent document confirming that the participant has been informed of all aspects of the clinical study.
  • Male or female participants, 18 to 65 years of age at time of screening.
  • Visual acuity of 20/200 or better.
  • Willingness to comply with required screening procedures, eye assessments, and follow-up visits, if needed.

Exclusion Criteria

  • Visual acuity worse than 20/200 in either eye
  • Complete blindness or diffuse vision loss in either eye
  • Clinical diagnosis of cognitive and motor diseases including but not limited to the following:
  • Neurodegenerative diseases such as dementia-like Alzheimer's disease, posterior cortical atrophy
  • Movement disorders such as Parkinson's disease and Parkinsonism tremors
  • Multiple sclerosis, stroke or any other neurological or physical conditions with paresis or plegia (i.e. weakness or paralysis of the limbs)
  • Eyes with a spherical equivalent of greater than +9 or -9 diopters where the corrective lens is too large to fit in the headset.

Arms & Interventions

Standard of Care

Other

This Cohort will undergo assessments for visual acuity, visual field, color vision, and self-paced saccade first via the current standard of care tests and then using the EyeMirage device and app.

Intervention: EyeMirage device (Device)

EyeMirage

Other

This Cohort will undergo assessments for visual acuity, visual field, color vision, and self-paced saccade first via the EyeMirage device and app, then via the standard of care tests.

Intervention: EyeMirage device (Device)

Outcomes

Primary Outcomes

Accuracy and Reliability of EyeMirage Test Results from Four Elements of Visual Testing in Comparison to Current Standard of Care

Time Frame: From enrollment to the end of follow-up visit at Day 30 + 7 days

Results of the eye assessments for visual acuity, visual field, color vision, and self-paced saccade using the EyeMirage device and app, and standard of care will be analyzed using the paired t-test. Insignificant p values (\>0.5) will indicate that there is no statistical difference between eye assessment results from the use of EyeMirage compared to those obtained from current standard of care clinical testing.

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Neuroptek Corporation Inc.
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (4)

Loading locations...

Similar Trials